» Articles » PMID: 36204643

Inflammasome Genetic Variants Are Associated with Tuberculosis, HIV-1 Infection, and TB/HIV-immune Reconstitution Inflammatory Syndrome Outcomes

Abstract

Background: Tuberculosis (TB) and AIDS are the leading causes of infectious diseases death worldwide. Here, we investigated the relationship between from single nucleotide polymorphisms (SNPs) of the NLRP3, CARD8, AIM2, CASP-1, IFI16, and IL-1β inflammasome genes, as well as the profiles of secreted proinflammatory cytokines (e.g., IL-1β, IL-18, IL-33, and IL-6) with the TB clinical profiles, TB-HIV coinfection, and IRIS onset.

Methods: The individuals were divided into four groups: TB-HIV group (n=88; 11 of them with IRIS), HIV-1 group (n=20), TB group (n=24) and healthy volunteers (HC) group (n=10), and were followed up at INI/FIOCRUZ and HGNI (Rio de Janeiro/Brazil) from 2006 to 2016. Real-time PCR was used to determine the genotypes of the Single Nucleotide Polymorphism (SNPs), and ELISA was used to measure the plasma cytokine levels. Unconditional logistic regression models were used to perform risk estimations.

Results: A higher risk for extrapulmonary TB was associated with the TT genotype (aOR=6.76; P=0.026) in the NLRP3 rs4612666 Single Nucleotide Polymorphism (SNP) and the C-C-T-G-C haplotype (aOR=4.99; P= 0.017) in the NLRP3 variants. This same Single Nucleotide Polymorphism (SNP) was associated with lower risk against extrapulmonary TB when the carrier allele C (aOR=0.15; P=0.021) was present. Among those with HIV-1 infections, a higher risk for TB onset was associated with the GA genotype (aOR=5.5; P=0.044) in the IL1-β rs1143634 Single Nucleotide Polymorphism (SNP). In contrast, lower risk against TB onset was associated with the A-G haplotype (aOR=0.17; P= 0.026) in the CARD8 variants. Higher IL-6 and IL-33 levels were observed in individuals with TB. A higher risk for IRIS onset was associated with CD8 counts ≤ 500 cells/mm (aOR=12.32; P=0.010), the presence of extrapulmonary TB (aOR=6.6; P=0.038), and the CT genotype (aOR=61.06; P=0.026) or carrier allele T (aOR=61.06; P=0.026) in the AIM2 rs2276405 Single Nucleotide Polymorphism (SNP), whereas lower risk against IRIS onset was associated with the AT genotype (aOR=0.02; P=0.033) or carrier allele T (aOR=0.02; P=0.029) in the CARD8 rs2043211 Single Nucleotide Polymorphism (SNP) and the T-G haplotype (aOR=0.07; P= 0.033) in the CARD8 variants. No other significant associations were observed.

Conclusions: Our results depict the involvement of genetic polymorphisms of crucial innate immunity genes and proinflammatory cytokines in the clinical outcomes related to TB-HIV coinfection.

Citing Articles

Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation.

Dinh P, Tran C, Dinh T, Ha H, Utegenova A, Ali A Biochem Biophys Rep. 2025; 41:101952.

PMID: 40034257 PMC: 11875834. DOI: 10.1016/j.bbrep.2025.101952.


Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis.

Pandey A, Li Z, Gautam M, Ghosh A, Man S Immunol Rev. 2024; 329(1):e13406.

PMID: 39351983 PMC: 11742652. DOI: 10.1111/imr.13406.


CARD8: A Novel Inflammasome Sensor with Well-Known Anti-Inflammatory and Anti-Apoptotic Activity.

Karakaya T, Slaufova M, Di Filippo M, Hennig P, Kundig T, Beer H Cells. 2024; 13(12.

PMID: 38920661 PMC: 11202080. DOI: 10.3390/cells13121032.


Serum cytokine biosignatures for identification of tuberculosis among HIV-positive inpatients.

Zhang H, Li L, Liu Y, Xiao W, Xu R, Lu M Thorax. 2024; 79(5):465-471.

PMID: 38490721 PMC: 11041549. DOI: 10.1136/thorax-2023-220782.


Identification of apoptosis-related gene signatures as potential biomarkers for differentiating active from latent tuberculosis via bioinformatics analysis.

Dai X, Zhou L, He X, Hua J, Chen L, Lu Y Front Cell Infect Microbiol. 2024; 14:1285493.

PMID: 38312744 PMC: 10834671. DOI: 10.3389/fcimb.2024.1285493.


References
1.
Martin M, Carrington M . Immunogenetics of HIV disease. Immunol Rev. 2013; 254(1):245-64. PMC: 3703621. DOI: 10.1111/imr.12071. View

2.
Antonelli L, Mahnke Y, Hodge J, Porter B, Barber D, DerSimonian R . Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood. 2010; 116(19):3818-27. PMC: 2981537. DOI: 10.1182/blood-2010-05-285080. View

3.
Robertson J, Meier M, Wall J, Ying J, Fichtenbaum C . Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006; 42(11):1639-46. DOI: 10.1086/503903. View

4.
Bana T, Lesosky M, Pepper D, Van der Plas H, Schutz C, Goliath R . Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors. BMC Infect Dis. 2016; 16(1):518. PMC: 5039896. DOI: 10.1186/s12879-016-1850-2. View

5.
Conesa-Botella A, Meintjes G, Coussens A, Van der Plas H, Goliath R, Schutz C . Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2012; 55(7):1004-11. PMC: 3436923. DOI: 10.1093/cid/cis577. View